Login to Your Account

KBP Biosciences raises $76M, gains new CEO, moves to U.S.

By David Ho
Staff Writer

Wednesday, January 10, 2018

HONG KONG – KBP Biosciences Co. Ltd. closed a $76 million series A financing to, among other things, advance its lead asset, KBP-5074, a mineralocorticoid receptor antagonist for cardiovascular disease entering phase IIb studies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription